Abeona Therapeutics Inc. (ABEO)
| Market Cap | 338.53M -4.3% |
| Revenue (ttm) | 25.52M +6,280.0% |
| Net Income | -62.89M |
| EPS | -1.18 |
| Shares Out | 57.18M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 912,886 |
| Open | 5.99 |
| Previous Close | 6.04 |
| Day's Range | 5.88 - 6.04 |
| 52-Week Range | 4.00 - 7.65 |
| Beta | 1.34 |
| Analysts | Strong Buy |
| Price Target | 18.86 (+218.58%) |
| Earnings Date | Aug 13, 2026 |
About ABEO
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platfor... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for ABEO stock is "Strong Buy." The 12-month stock price target is $18.86, which is an increase of 218.58% from the latest price.
News
Abeona Therapeutics reports Q2 EPS (35c), consensus (25c)
Reports Q2 revenue $11.38M, consensus $12.16M. “Our confidence in ZEVASKYN’s substantial opportunity is reinforced by our launch progress and experience to date as we engage with a growing number of…
Abeona Therapeutics price target lowered to $21 from $22 at Oppenheimer
Oppenheimer analyst Jeff Jones lowered the firm’s price target on Abeona Therapeutics (ABEO) to $21 from $22 and keeps an Outperform rating on the shares following quarterly results. The firm…
Abeona Therapeutics price target lowered to $15 from $20 at Alliance Global
Alliance Global lowered the firm’s price target on Abeona Therapeutics (ABEO) to $15 from $20 and keeps a Buy rating on the shares. The firm cites a moderate Zevaskyn adoption…
Abeona Therapeutics Earnings Call Transcript: Q2 2026
ZEVASKYN's Q2 2026 revenue rose 31% to $11.4M, with seven QTCs now active and 12 patients treated since launch. Operational and manufacturing challenges affected revenue recognition for some treatments, but CMS NTAP status and expanding access support future growth.
Abeona Therapeutics Quarterly report: Q2 2026
Abeona Therapeutics has published its Q2 2026 quarterly earnings report on August 13, 2026.
Abeona Therapeutics Earnings release: Q2 2026
Abeona Therapeutics released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update
- Q2 net ZEVASKYN® revenue increased 31% quarter-over-quarter to $11.4 million – - Five patients treated with ZEVASKYN in Q2 2026 and three treatments in Q3 2026 to-date; since launch, 12 treatments c...
Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
CLEVELAND, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the Company will host a conference call on Thursday, August 13, 2026 at 8:30 a.m. ET to discus...
CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®
CLEVELAND, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announ...
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awar...
Abeona Therapeutics activates Cincinnati Children’s as treatment center
Abeona Therapeutics (ABEO) announced the activation of Cincinnati Children’s as the seventh Qualified Treatment Center for the administration of Zevaskyn. Zevaskyn is an autologous gene-modified cellu...
Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®
CLEVELAND, July 21, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announ...
Abeona Therapeutics Transcript: AGM 2026
The meeting addressed director elections, executive compensation, auditor ratification, and equity plan amendments. All proposals passed except the amendment to remove the advance notice provision for director nominations.
Abeona Therapeutics Slides: Investor presentation
Abeona Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 10, 2026.
Abeona Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
ZEVASKYN's launch is progressing with growing patient access, strong demand, and expanding treatment center capacity. Payer coverage is robust, manufacturing is scaling, and ex-U.S. interest is high. Pipeline development continues, with profitability expected as patient volume increases.
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
CLEVELAND, May 26, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in June 2026:
Abeona Therapeutics Earnings Call Transcript: Q1 2026
ZEVASKYN's commercial launch drove a sharp revenue increase in Q1 2026, with strong demand, broad payer coverage, and expanding treatment center network. The company in-licensed a novel PSMA CAR-T asset, deprioritized ophthalmology, and expects monthly profitability as early as June.
Abeona Therapeutics Earnings release: Q1 2026
Abeona Therapeutics released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Abeona Therapeutics Quarterly report: Q1 2026
Abeona Therapeutics has published its Q1 2026 quarterly earnings report on May 13, 2026.
Abeona Therapeutics Slides: Q1 2026
Abeona Therapeutics has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 13, 2026.
Abeona Therapeutics reports Q1 EPS (30c), consensus (39c)
Reports Q1 revenue $8.72M, consensus $4.94M. “We are excited that an increasing number of patients at our QTCs are getting scheduled for ZEVASKYN slots this quarter,” said Vish Seshadri, president…
Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update
- Three patients treated with ZEVASKYN ® in Q1 2026 - - QTC network expands to six sites, with two new additions on the East Coast - - In-licensed radically novel engineered T-cell technology with ga...
Abeona Therapeutics® Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN®
CLEVELAND, May 11, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need...
Abeona Therapeutics® Announces Date of First Quarter Financial Results
CLEVELAND, May 04, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it will host a conference call on Wednesday, May 13, 2026 at 8:30 a.m. ET to discuss its financial r...
Abeona Therapeutics Proxy statement: Proxy filing
Abeona Therapeutics filed a proxy statement on May 4, 2026, providing details for shareholder voting and corporate governance matters.